Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Dublin, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/fgjml9/neurostimulation) has announced the addition of the "Neurostimulation - Global Strategic Business Report" report to their offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.
Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
This report analyzes the worldwide markets for Neurostimulation in US$ by the following Product Segments: Spinal Cord Stimulators (SCS), Deep Brain Stimulators (DBS), Sacral Nerve Stimulators (SNS), Vagus Nerve Stimulators (VNS), and Gastric Electric Stimulators (GES).
The United States is analyzed both in terms of value (US$) and volume (units) sales.
The report profiles 30 companies including many key and niche players such as
- Aleva Neurotherapeutics SA (Switzerland)
- BioControl Medical (Israel)
- Bioness Inc. (USA)
- Boston Scientific Corp. (USA)
- EnteroMedics Inc. (USA)
- LivaNova PLC (UK)
- Medtronic, Inc. (USA)
- NeuroPace, Inc. (USA)
- NeuroSigma, Inc. (USA)
- Nevro Corp. (USA)
- SPR Therapeutics, LLC (US)
- St. Jude Medical, Inc. (USA)
- Synapse Biomedical, Inc. (USA)
Key Topics Covered:
1. MARKET OVERVIEW
2. COMPETITIVE SCENARIO
3. GROWTH DRIVERS, TRENDS, & ISSUES
4. MACRO GROWTH DRIVERS FOR NEUROSTIMULATION INDUSTRY
5. TECHNOLOGICAL ADVANCEMENTS IN NEUROSTIMULATION MARKET
6. SELECT TARGETED INDICATIONS
7. PRODUCT OVERVIEW
8. NEUROSTIMULATION DEVICE APPROVALS
9. PRODUCT INNOVATIONS/INTRODUCTIONS
10. RECENT INDUSTRY ACTIVITY
11. FOCUS ON SELECT PLAYERS
12. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 30 (including Divisions/Subsidiaries - 31)
- The United States (23)
- Europe (7)
- - Germany (2)
- - The United Kingdom (2)
- - Rest of Europe (3)
- Middle East (1)
For more information visit http://www.researchandmarkets.com/research/fgjml9/neurostimulation
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Medical Devices, Neurology Devices
